

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
B cell lymphoma	Histone deacetylase (HDAC); proteasome	<p>Cell culture and mouse studies suggest a combination of proteasome and HDAC inhibitors could help treat primary effusion lymphoma (PEL). In cultured PEL cells, a combination of the HDAC inhibitor Zolinza vorinostat and the proteasome inhibitor Velcade bortezomib decreased proliferation and increased apoptosis compared with either drug alone. In a mouse xenograft model for human PEL, the combination caused tumor regression and increased survival compared with either drug alone. Next steps could include evaluating the combination in a clinical trial.</p> <p>Takeda Pharmaceutical Co. Ltd. and Johnson & Johnson market Velcade to treat multiple myeloma (MM) and mantle cell lymphoma (MCL).</p> <p>Merck & Co. Inc. and Taiho Pharmaceutical Co. Ltd. market Zolinza to treat cutaneous T cell lymphoma (CTCL).</p> <p>SciBX 6(20); doi:10.1038/scibx.2013.483 Published online May 23, 2013</p>	Patent and licensing status unavailable	<p>Bhatt, S. <i>et al.</i> <i>J. Clin. Invest.</i>; published online May 1, 2013; doi:10.1172/JCI64503</p> <p>Contact: Juan Carlos Ramos, University of Miami, Miami, Fla. e-mail: jramos2@med.miami.edu</p> <p>Contact: Izidore S. Lossos, same affiliation as above e-mail: ilossos@med.miami.edu</p> <p>Contact: Enrique A. Mesri, same affiliation as above e-mail: emesri@med.miami.edu</p>